Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Net Income (2019 - 2025)

Biodesix (BDSX) has disclosed Net Income for 7 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 52.08% year-over-year to -$4.0 million, compared with a TTM value of -$35.6 million through Dec 2025, up 16.76%, and an annual FY2025 reading of -$35.6 million, up 16.76% over the prior year.
  • Net Income was -$4.0 million for Q4 2025 at Biodesix, up from -$9.1 million in the prior quarter.
  • Across five years, Net Income topped out at -$4.0 million in Q4 2025 and bottomed at -$18.8 million in Q1 2023.
  • Average Net Income over 5 years is -$11.7 million, with a median of -$11.5 million recorded in 2021.
  • The sharpest move saw Net Income crashed 292.35% in 2021, then soared 52.08% in 2025.
  • Year by year, Net Income stood at -$13.2 million in 2021, then fell by 24.78% to -$16.4 million in 2022, then surged by 44.05% to -$9.2 million in 2023, then grew by 8.67% to -$8.4 million in 2024, then skyrocketed by 52.08% to -$4.0 million in 2025.
  • Business Quant data shows Net Income for BDSX at -$4.0 million in Q4 2025, -$9.1 million in Q3 2025, and -$11.6 million in Q2 2025.